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Abstract
The foundational advancements of John Gurdon and Shinya Yamanaka have improved understanding of dedifferen-
tiation of cells to a pluripotent state. The seminal discovery established a novel system to study disease pathogenesis, 
drug screening, and toxicity, as well as sprouted the new field of regenerative medicine. In this article, the method-
ology to obtain dedifferentiated cells, known as induced pluripotent stem (iPS) cells, subsequent validation, and 
application of which are reviewed. The experiments investigated here aim to demonstrate the capacity of iPS cells to 
replace the ethically-gray human embryonic cells by developing human livers and viable, healthy animals. It is con-
cluded that the reported methods pave the way for a bright future of iPS cell application in both basic and applied 
sciences.
Introduction
 Stem cells have immense 
potential for treatment of diseases 
including diabetes and heart dis-
ease through regenerative cell based 
therapies1. As a result, the scientific 
community has put forth tireless 
effort to better understand these 
cells and their unique capacity to 
differentiate into the plethora of 
cells observed in biological systems. 
The undertaking began with basic 
science experimentation where many 
researchers turned to the ovum to 
elucidate the beginning steps of cell 
differentiation. John Gurdon, win-
ner of the Nobel Prize in Physiology 
or Medicine in 2012, was among 
the first to investigate what changes 
the somatic cell nucleus undergoes 
during embryonic differentiation2. 
After isolating recipient eggs and 
tagging donor embryo nuclei from 
Xenopus laevis, Gurdon exploited 
the previously established nuclear 
transplantation protocol to move the 
tagged nuclei into the donor eggs. 
Gurdon observed that some trans-
plant frogs could grow to a normal 
size, morphology, and have normal 
reproductive function similar to 
non-transplant frogs. From his work, 
it was concluded that somatic cell 
nuclei had all genes necessary for 
normal developmental progression3. 
Strelchenko took the same principle 
of somatic cell nuclear transfer and 
developed a novel technique that 
fused a somatic cell with a human 
embryonic stem (hES) cell. By 
exploiting pre-existing factors in the 
cytoplast of hES cells, Strelchenko 
was able to culture cells harboring 
the nuclear genome of the somatic 
cell but had the differentiation ca-
pacity of hES cells4. Although amaz-
ing, both Gurdon and Strelchenko’s 
work lack an understanding of the 
factors associated with reverting a 
somatic nuclei to one reminiscent of 
an embryonic nuclei. 
 
The Generation of iPS Cells
 In a ground-breaking en-
deavor worthy of sharing the Nobel 
Prize in Physiology or Medicine with 
Gurdon in 2012, Shinya Yamanaka 
of Kyoto University identified the 
elusive factors necessary to induce 
pluripotency5,6. To do this, Yamana-
ka developed a retrovirus containing 
green fluorescent protein (GFP) and 
four essential factors later coined the 
Yamanaka cocktail: Oct3/4, Sox2, 
Klf4, c-Myc. Adult human dermal 
fibroblasts (HDF) that had previous-
ly been supplemented with artificial 
mouse receptors for retrovirus were 
then transfected using the previously 
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developed retrovirus. Oct3/4 and 
Sox2 are known to encode for tran-
scription factors associated with the 
developmentally critical homeodo-
main proteins as well as contribute 
to pluripotency and self-renewal7. 
Klf4 is a bona fide component of the 
pre-transcriptional machinery for 
Tert expression through interactions 
with ß-catenin8. C-Myc is tradi-
tionally known to be a transcription 
factor but has also been proven to 
be responsible for promoting forma-
tion of euchromatin in the human 
genome9. Six days after transfection, 
Yamanaka and colleagues collected 
cells via trypsinization and subse-
quently plated collected cells with 
SNL feeder cells10.
 The remaining majority 
of the protocol implemented by 
Yamanaka aimed to isolate and cul-
ture iPS cells. This started with first 
growing cells in a medium contain-
ing 10% fetal bovine serum (FBS). 
The medium was shortly thereafter 
replaced with a medium designed 
for primate ES cells supplemented 
with basic fibroblast growth fac-
tor (bFGF). After a full month of 
culturing, flat colonies resemblant 
of hES colonies were isolated via 
mechanic disaggregation and then 
transferred to fresh primate ES cell 
medium containing bFGF. At this 
stage, individual cells and cell col-
onies displayed morphologic char-
acteristics similar to hES cells; these 
similarities include large nuclei with 
little cytoplasm and aggregates that 
formed in tightly packed flat colo-
nies. In hES cell cultures, cells locat-
ed in the center of aggregates tend to 
differentiate. At this stage of exper-
imentation, the same phenomenon 
was observed in the hES-like cell 
aggregates. To sustain the suspected 
undifferentiated capacity of cells that 
resembled hES, cells were transferred 
to plates in mouse embryo fibroblast 
(MEF)-conditioned ES cell medium. 
These cells were then tested for pluri-
potency and were then on referred 
to as induced pluripotent stem (iPS) 
cells. To confirm that iPS cells were 
analogous to hES cells, Yamanaka 
compared iPS cell similarity to hES 
cells based on the following criteria: 
morphology, proliferation, feeder 
dependence, surface markers, gene 
expression, promoter activities, tel-
omerase activities, in-vitro differen-
tiation to three different germ layers, 
and teratoma formation. Yamanaka 
also observed that transgenic genes 
had been silenced by the time the 
cell reached an hES-like state10. 
 
Validation of iPSCs
 Since the establishment of 
the Yamanaka cocktail, researchers 
hoped that iPS cells could replace 
the ethically controversial ES cells 
and set out to do so. Kristin Baldwin 
of the Dorris Neuroscience Center 
at Scripps Research Institute has 
recently generated iPS-derived mice 
to validate their candidacy to sub-
stitute for ES cells11,12. Baldwin used 
the procedure developed by Yamana-
ka but added a method to control 
expression of the Yamanaka cocktail 
through a tetO promoter. The tetO 
promoter is activated by a reverse 
tetracycline transactivator (rtTA) 
protein in the presence of tetracy-
cline analogue doxycycline (dox). 
In this way, Baldwin could drive 
expression of the Yamanaka cocktail 
with the addition of dox and rtTA. 
Baldwin also exposed MEFs to a 
histone deacetylase inhibitor valproic 
acid (VPA) to enhance reprogram-
ming efficiency and select against 
incompletely reprogrammed cells by 
restricting cellular division11. 
 After developing several iPS 
cell lines, Baldwin strived to generate 
an iPS-derived adult mouse. To do 
so, Baldwin first conducted a tetra-
ploid complementation assay. This 
was used to develop embryos with 
an albino phenotype from each of 
the iPS cell lines. This was accom-
plished by fusing the two cells of 
an embryo at the two cell stage to 
make one tetraploid cell. Normal 
development can take place up to 
blastocyst formation. At the blasto-
cyst stage, the cell is anucleated and 
fused with a diploid iPS cell that will 
have an agouti phenotype11,13. The 
agouti blastocysts were then inject-
ed into separate albino female mice 
and pups were collected a day prior 
to estimated delivery via Caesar-
ean section. During early stages of 
development, some pups from each 
cells line were either cannibalized, 
non-viable, or viable. All pups were 
observed to have normal morphol-
ogies. Of the non-viable pups, most 
presented with respiratory compli-
cations. Adult male iPS cell-derived 
mice later demonstrated successful 
reproductive capacity to produce vi-
able offspring11. Although Baldwin’s 
work provided an initial foundation 
demonstrating that iPS cells had the 
potential to replace ES cells, research 
was still far from developing satisfac-
tory results to initiate clinical stud-
ies. 
 Using Baldwin and Yamana-
ka’s concepts and techniques, 
Hideki Taniguchi of Yokohama 
City University in Japan set out to 
demonstrate iPS cells are bona fide 
substitutes of hES cells by creating a 
human liver from an iPS cell organ 
bud14. Taniguchi prepared hepatic 
endoderm cells from human iPS 
cells (iPSC-HEs). To mimic early 
organogenesis of the liver, human 
iPSC-HEs were grown in conjunc-
tion with a stromal cell population 
to activate the FGF and BMP path-
ways. The stromal cell population 
was composed of human umbilical 
vein endothelial cells (HUVECs) 
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and human mesenchymal stem cells 
(MSCs). After 48 hours of plating, 
the cell culture was observed to 
self-organize into three dimensional 
aggregates. These aggregates were 
proven to be iPS cell-derived liv-
er buds (iPSC-LBs) via antibody 
staining. To see if the liver-bud 
cells more closely resembled human 
livers or human iPS cells derived 
from mature hepatocyte-like cells, 
Taniguchi implemented microarray 
analysis to assess the expression of 83 
genes known to be upregulated dur-
ing liver development. Microarray 
analysis showed that the liver-bud 
cells resembled human livers 22-40 
weeks into gestation. Qualitative 
analysis with fluorescence-activated 
cell sorting (FACS) indicated that 
cells expressed proteins associated 
with adult livers; these proteins 
include the tight junction protein 
zona occludens 1 (ZO1), ALB, 
CK8/18, asialoglycoprotein receptor 
1 (ASGR1), and collagen IV. Histo-
logic examination revealed the pres-
ence of a hepatic cord-like structure 
- a defining characteristic of adult 
livers15.
 After developing viable organ 
buds, Hideki Taniguchi tested if the 
iPSC-LBs had the capacity to gener-
ate fully functional livers. Using the 
cranial window model, liver-buds 
were transplanted and monitored. 
Microarray analysis indicated that 
human iPSC-LBs were more similar 
to matured hepatocytes than iPSC-
MHs. Considering that hepatocytes 
are the main cell of the liver tissue, 
this provided an encouraging indica-
tor that an iPSC-LB derived liver 
had formed. To assess its functional-
ity, mice with the human iPSC-LB 
transplant were injected with either 
ketoprofen or debrisoquine. Keto-
profen and debrisoquine are drugs 
known to be metabolized differently 
in humans than in mice. In serum 
and urine samples collected from 
mice transplanted with the human 
iPSC-LBs, metabolites unique to a 
human liver were found. Taniguchi 
then assessed the metabolome for 
metabolites of sugars, amino acids 
and nucleotides. Of the 222 metabo-
lites assessed, the metabolome bore 
strong resemblance to a human adult 
liver rather than human iPS cells. 
In addition to its metabolic capabil-
ity, the human iPSC-LB-derived 
liver displayed full vascularization15. 
This research validated iPS cells as 
candidates for replacing ES cells and 
paved the way for their application 
in regenerative medicine.
Current Status of iPSC 
Application
 Masayo Takahashi of RIKEN 
laboratory in Japan has recently 
received government approval in 
July 2013 for a pilot study using iPS 
cell therapy in wet-type age-related 
macular degeneration (AMD)16. 
Although the cause of AMD is 
unknown, the disease has been well 
characterized. AMD patients pres-
ent with an abnormal growth of new 
blood vessels in the tissue proximal 
to the eye. This abnormal growth 
causes damage to the retinal pig-
ment epithelium (RPE) and sensory 
retina. Takahashi plans to collect a 
biopsy of skin cells from each patient 
to produce iPS cells unique to each 
patient. The iPS cells can then be 
differentiated to form a monolayer 
cell culture of RPE. After surgically 
removing damaged RPE and other 
undesired growths, the missing 
epithelium can be replaced by the 
monolayer of iPS cell-derived RPE 
cells. The initial treatment would 
then be followed up by a one year 
monitoring period and then a three 
year period of follow up examina-
tions. The current challenges for the 
pilot study involve taking a biopsy 
and inhibiting the formation of 
tumors. Dr. Takahashi has thus far 
approved six patients for treatment16. 
The risks associated with Takahashi’s 
pilot study may seem few, but there 
are many experimental hurdles to 
overcome prior to transplantation. 
Current Issues and Future of 
iPSCs
 The problems faced with iPS 
cell research stem from the recent 
evolution of iPS cells and the con-
sequent ambiguities of a system not 
well characterized. For example, the 
mechanism by which the Yamanaka 
cocktail induces pluripotency is not 
well understood. An understanding 
of the signal transduction cascades 
involved may resolve other issues 
such as low iPS cell yield. In Ya-
manaka’s study, 5 x 104 fibroblasts 
were used to yield roughly ten hES 
cell-like colonies. The undesirably 
low induction efficiency may be 
due to one or a combination of the 
following factors: low efficiency of 
HDF transduction, mechanistic 
difficulty teasing apart iPS cells from 
differentiated cells, or the transfec-
tion integration site may be site-
specific at a loci10. Similar challenges 
beget similar complications as Bald-
win had found with her experimen-
tation that had low yields for iPS 
cell-derived mice. Baldwin reports 
that 0.3-13% of iPS cells were able 
to generate mice. Another problem 
emerged as roughly 20% of viable 
mice developed tumors resulting 
from c-Myc reactivation11. The high 
rate of tumor development could 
also be attributed to the approximate 
20 retroviral integration sites per 
clone10. Due to the absence of reli-
able transplantation techniques for 
therapeutic application, Taniguchi 
also faced issues of low yield when 
transplanting iPSC-LBs15. Not only 
are iPS cells and iPS cell derivatives 
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challenging to generate, they are 
notidentical to hES cells. An ideal 
candidate to substitute hES cells 
would have high similarity in expres-
sion, morphology, and proliferation 
capacity. Some differences have been 
highlighted through microarray 
analyses. Researchers have conclud-
ed that iPS cells are like ES cells 
but are not ES cells10. Due to their 
dissimilarity and difficulty to gener-
ate, many researchers have turned to 
developing alternative techniques to 
induce pluripotency. 
 Dr. Andrew Wan of the 
Institute of Bioengineering and 
Nanotechnology in Singapore is one 
of  many working on developing a 
non-viral vector method to induce 
pluripotency in somatic cells. Wan 
has developed a protein delivery 
system that requires the synthesis of 
a long hydrocarbon chain with hy-
drophilic functional groups incorpo-
rated at both ends of the molecule; 
this system is formerly known as a 
cationic bolammphiphile protein 
delivery system18. The delivered pro-
teins are able to induce pluripotency 
at low toxicity but also low yield. 
Because this system requires the 
synthesis of an intricate cationic bo-
laamphiphile complex, the technique 
is challenging to some of the most 
experienced scientists19. Currently, 
the most reliable method to revert 
cells back to an ES-like state relies 
on the transfection of the Yamanaka 
cocktail.
Closing Remarks
 IPS cell cultures can replace 
hES cells for understanding dis-
ease mechanisms, drug screening, 
and toxicology10. Using Taniguchi’s 
method of developing human liv-
ers in mice models, in vivo drug 
screening can be performed to test 
for harmful effects or metabolites. 
Taniguchi’s experiment also validates 
a discussion of using organ-bud 
transplantation as an alternative 
avenue for the generation of organs 
when treating organ failure15. Since 
iPS cells can be made from ordinary 
fibroblasts, such iPS cells are unique 
to the patient because they will 
harbor the same nuclear genome as 
the patient10. This allows for patient 
specific cultures that, in principle, 
should reduce or eliminate patient 
transplant rejection. Though iPS 
provides an optimistic future for 
basic and applied science research, 
further characterization is necessary.
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